Engineered Bacteriophage Multivalent Vaccine Display
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccination methods, such as live/active, killed, or subunit vaccines, often require multiple doses and may not induce strong or lasting immune responses, especially against rapidly evolving pathogens, and can be limited by the use of adjuvants that may cause toxicity.
Innovation Solution
Development of engineered multivalent bacteriophages that display multiple exogenous polypeptides derived from pathogenic proteins on their surface, which can stimulate both humoral and cellular immune responses without the need for adjuvants, providing broad immunity against multiple pathogens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live/active or killed vaccines are used, then immune response can be stimulated, but multiple doses are required and the response may not be strong or lasting
Solution Approach 1:
The vaccine uses bacteriophage particles as a composite delivery system that combines multiple functions: the phage capsid displays multiple antigenic polypeptides from different pathogens, while the phage structure itself acts as an adjuvant to stimulate strong immune responses. This composite approach eliminates the need for multiple doses of traditional vaccines.
2Reliability
If adjuvants are added to enhance immune response, then vaccination effectiveness improves, but toxicity may increase
Solution Approach 1:
The bacteriophage vaccine is self-adjuvanting, meaning the phage particle structure itself provides the immunostimulatory function traditionally requiring separate adjuvant components. The phage capsid and associated molecules naturally stimulate both humoral and cellular immune responses without requiring additional toxic adjuvants.
3Reliability
If single-pathogen vaccines are used, then specific immunity is provided, but protection against multiple pathogens requires multiple vaccines
Solution Approach 1:
The bacteriophage is engineered to display multiple different antigenic polypeptides on its surface, enabling a single vaccine particle to provide immunity against multiple different pathogens. This multi-functional approach consolidates what would otherwise require multiple separate vaccines into one administration.
4Ease of manufacture
If traditional vaccine platforms are used, then manufacturing is established, but adaptation to rapidly evolving pathogens is limited
Solution Approach 1:
The bacteriophage vaccine platform is dynamically adaptable - the genetic sequences encoding antigenic polypeptides can be rapidly modified to match evolving pathogens while maintaining the same phage delivery system. This allows the vaccine to be updated quickly in response to pathogen evolution without requiring complete redesign of the manufacturing platform.
Data Source
AI summary
Engineered bacteriophage and methods of forming the bacteriophage are described. Multivalent bacteriophage are described that can include multiple different exogenous polypeptides at a surface of the capsid head. Vaccines and methods of forming and using vaccines are described. A vaccine can include an engineered bacteriophage that exhibits an immunogenic exogenous polypeptide at a surface of the bacteriophage. Multivalent bacteriophage and immunogenic bacteriophage are free of nucleic acids encoding the exogenous polypeptide(s).